Pyrocardan® implant interposition in the trapeziometacarpal joint: outcomes at a minimum 10 years' follow-up.

Hand surgery & rehabilitation Pub Date : 2024-12-28 DOI:10.1016/j.hansur.2024.102074

Grégoire Chiarella, Ludovic Ardouin, Flore-Anne Lecoq, Clara Sos, Philippe Bellemère

{"title":"Pyrocardan® implant interposition in the trapeziometacarpal joint: outcomes at a minimum 10 years' follow-up.","authors":"Grégoire Chiarella, Ludovic Ardouin, Flore-Anne Lecoq, Clara Sos, Philippe Bellemère","doi":"10.1016/j.hansur.2024.102074","DOIUrl":null,"url":null,"abstract":"Objective: We present long-term results for the Pyrocardan®, a pyrocarbon trapeziometacarpal interposition implant used for the treatment of osteoarthritis of the thumb.Methods: Between March 2009 and May 2013, 199 arthroplasties were performed in a single hand center, in 184 patients by 6 hand surgeons. 107 implants were followed up for a mean 137 months (range, 120 to 168 months). 82 patients (89 implants) were lost to follow-up.Results: Median age was 57 years, with 15 patients (14.2%) aged ≤50 years. At last follow-up, functional scores were significantly improved compared to preoperative data: pain rating, 0.4/10 versus 7.2/10; Patient-Rated Wrist/Hand Evaluation, 4/100 versus 61/100; Quick Disabilities of the Arm, Shoulder and Hand, 9/100 versus 54/100. Range of motion and strength were comparable to the contralateral side. Radiographic analysis showed that 82% of implants were correctly positioned. No implant dislocation was observed. There were 6 re-operations, 5 of which in the short term. Overall implant survival was 94.3%, with 44.7% loss to follow-up.Conclusion: Pyrocardan® interposition arthroplasty is a valid alternative for the treatment of osteoarthritis of the thumb.Level of evidence: IV.","PeriodicalId":94023,"journal":{"name":"Hand surgery & rehabilitation","volume":" ","pages":"102074"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hand surgery & rehabilitation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.hansur.2024.102074","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: We present long-term results for the Pyrocardan®, a pyrocarbon trapeziometacarpal interposition implant used for the treatment of osteoarthritis of the thumb.

Methods: Between March 2009 and May 2013, 199 arthroplasties were performed in a single hand center, in 184 patients by 6 hand surgeons. 107 implants were followed up for a mean 137 months (range, 120 to 168 months). 82 patients (89 implants) were lost to follow-up.

Results: Median age was 57 years, with 15 patients (14.2%) aged ≤50 years. At last follow-up, functional scores were significantly improved compared to preoperative data: pain rating, 0.4/10 versus 7.2/10; Patient-Rated Wrist/Hand Evaluation, 4/100 versus 61/100; Quick Disabilities of the Arm, Shoulder and Hand, 9/100 versus 54/100. Range of motion and strength were comparable to the contralateral side. Radiographic analysis showed that 82% of implants were correctly positioned. No implant dislocation was observed. There were 6 re-operations, 5 of which in the short term. Overall implant survival was 94.3%, with 44.7% loss to follow-up.

Conclusion: Pyrocardan® interposition arthroplasty is a valid alternative for the treatment of osteoarthritis of the thumb.

Level of evidence: IV.

查看原文